“2cureX is honored that Dr. John L. Marshall and Dr. Jesús García-Foncillas have accepted to assist us in defining the next generation of personalized oncology tools based on the IndiTreat® test. Not only will 2cureX benefit from their impressive expertise within treatment of gastro-intestinal (GI) cancers; but also, their understanding of how to establish an effective personalized treatment package, including a functional test like IndiTreat®, that fits into daily clinical practice” said Ole Thastrup, CSO and Founder of 2cureX.
Dr. Marshall is Chief, Hematology and Oncology at Georgetown University Hospital, and Professor of Medicine and Oncology at Georgetown University in Washington D.C. He is Director at the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown University and Director of Gastrointestinal Oncology at the Lombardi Comprehensive Cancer Center. Dr. Marshall has authored more than 160 articles (Pubmed) and is an internationally recognized expert in new drug development for GI cancer, with expertise in phases I - III trial design. He has been the Principal Investigator for more than 100 clinical trials.
Dr. Garcia-Foncillas is currently the Director of the University Cancer Institute and the Department of Oncology at the University Hospital “Fundacion Jimenez Diaz”, part of Fresenius Helios, the largest private hospital network in Europe and Latin America. He is also Professor of Oncology at the Autonomous University of Madrid (UAM), and Director of the Professorship on Molecular Individualized Medicine UAM-Merck. He combines this with the roles of Director of the Translational Oncology Division at the Health Research Institute FJD-UAM and Chairman of the Comprehensive Cancer Program of four University Hospitals in Madrid. He was awarded with the 2014 Prize to the best Spanish Researcher in Oncology. More recently, professor García-Foncillas has been awarded the 2020 National Prize of the Royal National Academy of Medicine of Spain, being elected member of the same institution and has also been distinguished as the best researcher in Oncology 2020. Prof. Garcia-Foncillas is conducting many clinical trials from phase I to phase III and is author of more than 275 articles (PubMed) and several books on Cancer.
“It is a pleasure for me to welcome two exceptional oncologists as Dr García-Foncillas and Dr Marshall to 2cureX” comments Fernando Andreu, CEO of 2cureX and he continues “Knowledge around cancer is constantly expanding and we need to ensure our products and services fit in this changing environment. The views of our advisors will be critical to guide our decisions on product design, validation, and commercialization to make IndiTreat® a widely used tool in the growing field of Precision Oncology”.
For more information about 2cureX:
Fernando Andreu, Chief Executive Officer
Telephone: +45 2279 5399
2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors that functionally resemble the patient's tumor and identifies the approved cancer treatment that most effectively kills the patient's tumor. Immediately after the test, the patient is given the selected treatment.
The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products help patients at different stages of colorectal cancer and other solid cancers.
According to several published reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide1, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%2. Despite this, only one third of all cancer therapy decisions are currently supported by the result of an IVD.
The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
Certified Adviser: Redeye AB, +46 8 121 576 90, email@example.com
Följande bilagor finns för nedladdning:
2021 07 29 - PR Advisory Board